RESOLUTION

Subject: Anti-Obesity Medications

Submitted by: Monalisa Tailor, MD

Referred to: Reference Committee

WHEREAS, in 2015, the American Medical Association recognized obesity as a chronic disease. Obesity is directly linked to 230 other diseases, and 13 specific types of cancer; and WHEREAS, obesity rates continue to increase in the country and sadly, Kentucky ranks 1st in childhood obesity and 2nd in adult obesity; and

WHEREAS, with a 10% body weight loss, many of these conditions improve, and a 20% weight loss or more, they can resolve. However, this goal is quite difficult to achieve. With diet and exercise alone only about 5% of the population can achieve and maintain this level of weight loss; and

WHEREAS, when we combine lifestyle modifications with the newer class of GLP1 drugs, approximately 50% of patients can achieve at least 10% body weight loss with a smaller percentage achieving 20% weight loss or more; now, therefore, be it

RESOLVED, that KMA support the use of anti-obesity medications in treating patients with obesity if they are safe, effective and have a sustained impact with lifestyle modifications; and be it further

RESOLVED, that the KMA advocate for better access to anti-obesity medications for all patients appropriately prescribed those medications.